Verona Pharma plc
Develops innovative therapies for chronic respiratory diseases like COPD and asthma.
VRNA | US
Overview
Corporate Details
- ISIN(s):
- US9250501064
- LEI:
- Country:
- United States of America
- Address:
- 3 MORE LONDON RIVERSIDE, LONDON
- Website:
- https://www.veronapharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs. The company's primary focus is on its lead product candidate, ensifentrine, a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and potentially other respiratory conditions like asthma. Following an acquisition, the company is set to operate as a subsidiary of Merck & Co., Inc. (known as MSD outside the U.S. and Canada) to complement Merck's portfolio of treatments for cardio-pulmonary diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Verona Pharma plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Verona Pharma plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Verona Pharma plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
